Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
May 29, 2024 12:57 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $48.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
The analyst comments "Its always tough to draw conclusions from such small data sets (N=4) and ever more so in an open-label, uncontrolled setting, where the... More
